USD
+$0.00
(+0.00%
)At Close (As of Sep 18, 2025)
$37.27M
Market Cap
-
P/E Ratio
-1.6
EPS
$19.48
52 Week High
$4.16
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $21M |
Total Revenue | $25M |
Cost Of Revenue | $3.8M |
Costof Goods And Services Sold | $3.8M |
Operating Income | -$12M |
Selling General And Administrative | $31M |
Research And Development | $2.4M |
Operating Expenses | $34M |
Investment Income Net | - |
Net Interest Income | $572K |
Interest Income | $572K |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $1.3M |
Income Before Tax | -$12M |
Income Tax Expense | -$93K |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$12M |
Comprehensive Income Net Of Tax | - |
Ebit | -$12M |
Ebitda | -$11M |
Net Income | -$12M |
Field | Value (USD) |
---|---|
Total Assets | $20M |
Total Current Assets | $16M |
Cash And Cash Equivalents At Carrying Value | $3.5M |
Cash And Short Term Investments | $3.5M |
Inventory | $1.7M |
Current Net Receivables | $1.4M |
Total Non Current Assets | $4.2M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | $8.5M |
Other Current Assets | $1.3M |
Other Non Current Assets | - |
Total Liabilities | $13M |
Total Current Liabilities | $9.2M |
Current Accounts Payable | $1.8M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $361K |
Total Non Current Liabilities | $3.8M |
Capital Lease Obligations | $4.1M |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $4.1M |
Other Current Liabilities | $6.5M |
Other Non Current Liabilities | - |
Total Shareholder Equity | $7.5M |
Treasury Stock | - |
Retained Earnings | -$177M |
Common Stock | $7K |
Common Stock Shares Outstanding | $7.5M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$6.9M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $1.3M |
Capital Expenditures | $0 |
Change In Receivables | - |
Change In Inventory | $713K |
Profit Loss | - |
Cashflow From Investment | -$8.5M |
Cashflow From Financing | $8.4M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$12M |
Field | Value (USD) |
---|---|
Gross Profit | $21M |
Total Revenue | $25M |
Cost Of Revenue | $3.8M |
Costof Goods And Services Sold | $3.8M |
Operating Income | -$12M |
Selling General And Administrative | $31M |
Research And Development | $2.4M |
Operating Expenses | $34M |
Investment Income Net | - |
Net Interest Income | $572K |
Interest Income | $572K |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $1.3M |
Income Before Tax | -$12M |
Income Tax Expense | -$93K |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$12M |
Comprehensive Income Net Of Tax | - |
Ebit | -$12M |
Ebitda | -$11M |
Net Income | -$12M |
Sector: HEALTHCARE
Industry: MEDICAL DEVICES
Electrocore, Inc. is a commercial-stage medical device company based in Rockaway, New Jersey, focused on innovating and delivering non-invasive vagus nerve stimulation (nVNS) therapies to address various neurological conditions. With a strong commitment to advancing therapeutic options, Electrocore has developed a portfolio that aims to improve patient outcomes in chronic pain, migraine, and epilepsy, positioning itself as a front-runner in the neuromodulation space. The company's cutting-edge technology and robust clinical data underscore its potential to transform healthcare practices and enhance the quality of life for patients.